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Abstract: The aim of this study is to provide an overview and understand the strength of evidence
and the extent of potential biases and the validity of claimed associations between the use of statins
and cancer mortality or survival. We performed a comprehensive umbrella review of meta-analyses
and systematically appraised the relevant meta-analyses of observational studies on the associations
between statin use and cancer mortality or survival in various kinds of cancer. We searched the
PubMed database and screened the reference list of relevant articles. We obtained the summary effect,
95% confidence interval, heterogeneity, and also examined small study effects and 95% prediction
intervals for effect sizes, and the level of evidence was determined from the criteria. Regarding cancer
mortality, statin use showed convincing evidence for an association with a reduced cancer-specific
mortality rate for colorectal cancer. Four associations with reduced all-cause mortality (for breast
cancer, colorectal cancer, endocrine-related gynecological cancer, and ovarian cancer) had a suggestive
evidence. Moreover, analyses in nine cancers showed a weak level of evidence, while the remaining
15 did not indicate significant changes in either direction. Although there was a preventive effect of
statin on cancer mortality in some cancer types, the evidence supporting the use of statins to reduce
cancer mortality or survival was low.
Keywords: statin; cancer mortality; cancer survival; meta-analysis; umbrella review
1. Introduction
Cancer is a disease caused by an uncontrolled division of abnormal cells in a part of the body due to
breakdown in the processes which control cell proliferation, differentiation, and death of particular cells.
According to the recent incidence and mortality data, there were an estimated 14.1 million new cancer
cases and 8.2 million cancer deaths worldwide in 2012 [1]. Recently, the relative survival of patients
with cancer has gradually increased over time [2] and the new anti-cancer regimens have broadened
the therapeutic options for many cancer patients significantly. Nevertheless, cancer mortality is still
high in most cancer types.
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β-Hydroxy β-methylglutaryl-CoA (HMG-CoA), also known as 3-hydroxy-3-methylglutaryl-CoA,
is an intermediate in the mevalonate and ketogenesis pathways, and its inhibitors (statins) have been
used to reduce plasma cholesterol levels for preventing coronary heart disease [3]. Although there have
been earlier concerns on the carcinogenicity of statins, such as initiation or promotion of cancers in
rodents at concentrations equivalent to those commonly prescribed in humans [4], there has also been
growing evidence which suggests that statins could have a chemopreventive effect against cancer [5,6]
Although the potential mechanisms of the anti-cancer effect of statin are still elusive, inhibition of
cancer cell growth, promotion of apoptotic cell death and inhibition of matrix metalloproteinases are
involved in processes such as tumor growth, invasion, and metastasis have been suggested [7–9].
Recently, there have been many epidemiologic studies and meta-analyses on the beneficial effect
of statin on cancer incidence and mortality or survival. However, the results were conflicting on
these associations [10–12]. In addition, some of these reported associations could be caused by biases.
We have previously examined the association between statin use and cancer incidence by performing
an umbrella review by assessing the level of evidence [13], but there has been no study focusing
on cancer mortality. Therefore, to provide an overview of the strength of evidence, the extent of
potential biases and the validity of the claimed associations between statin use and cancer mortality or
survival, we performed an umbrella review of the evidence across the published meta-analyses on the
associations between statin use and various kinds of cancer mortalities or survivals.
2. Methods
We performed an umbrella review of meta-analyses and systematic reviews on the associations
between statin use and cancer mortality or survival. This umbrella review and meta-analysis was
conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [14]. The PRISMA checklist is shown in Supplementary Materials.
2.1. Methods for Literature Search
Two investigators (G.H.J. and J.I.S) searched the data and any discrepancies were resolved by
discussion and consensus. We searched the literature using the PubMed database and selected the
articles written in English. The last search was performed in August 2018. The following keywords
were used to find the relevant articles: ‘(hydroxymethyl glutaryl-CoA reductase inhibitor OR statin)
AND (cancer OR neoplasm OR tumor OR malignancy) AND (meta-analysis OR systematic review)
AND (survival OR mortality OR death)’. We carefully reviewed the retrieved articles by examining
titles, abstracts and full texts, and then determined whether the article could be included or excluded.
The detailed search strategy is shown in Figure 1.
2.2. Eligibility Criteria and Data Extraction
We included meta-analyses and systematic reviews of both RCTs and observational studies (cohort
or case-control studies) on the relationship between statin use and cancer mortality or survival. However,
we could not find any meta-analysis of RCTs on this association and therefore, only observational
studies were included and analyzed. Any mortality or survival outcomes were included and five
outcomes (all-cause mortality, cancer-specific mortality, recurrence-free survival, progression-free
survival, and disease-free survival) were found in the included meta-analyses on the associations
between statin use and cancer mortality or survival. Narrative review articles, in vitro or animal studies
and genetic association meta-analyses were excluded in our study. Meta-analyses with insufficient
data were also excluded. If there are several meta-analysis articles on the same topic and outcome, we
included all the meta-analyses to see whether there are any discrepancies among them.
We obtained the original data from eligible meta-analyses, and extracted and summarized
information on the first author, year of publication, the type of cancer, the type of outcome (all-cause
mortality, cancer-specific mortality, recurrence-free survival, progression-free survival, and disease-free
survival), the study design, the number of included studies, the number of case and total participants,
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and the random effects with 95% CI. In addition, we extracted the raw datasets of each individual
study for the further re-analysis of meta-analysis.J. Clin. Med. 2020, 9, 326 3 of 20 
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2.3. Statistical Analysis
We firstly reanalyzed each meta-analysis result for the relationship between statin use and cancer
mortality or survival. We found that most published meta-analyses presented only the results of
random effects and therefore, we p rfo med not only random-effects meta-analysis but also fixed-effect
meta-analysis. In ad ition, if there were overlapping meta-analyses on the same topic, we pooled
all the datasets of individual studies from eligible meta-analyses according to the type of cancer or
study design and performed re-meta-analysis after eliminating the overlapping individual studies and
including missing individual studies. We presented the summary effect size, 95% CI and p-value with
both random- and fixed-effects. All re-analyses in this study were performed using Comprehensive
Meta-Analysis software ver.3.3.070 (Borenstein, Englewood, NJ, USA).
For each meta-analysis, we re-analyzed the individual studies and estimated the summary effects
and 95% CI using both fixed and inverse variance random- and fixed-effects methods [15]. We also
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calculated and presented the 95% prediction intervals (PIs), which address the dispersion of effects in
95% of cases the true effect in a new study will fall within the PIs and further account for between-study
heterogeneity [16], whereas CI reflect the accuracy of the mean.
Heterogeneity across the individual studies was assessed using I2 metric of inconsistency and the
p-value of the Cochrane Q test [17]. Publication bias was evaluated by using Egger’s regression test [18].
Small study effects were used to detect publication and report bias [19,20]. If Egger’s regression test
was significant (p-value < 0.10) in random-effects meta-analyses, we judged that the meta-analysis has
small-study effects.
2.4. The Criteria to Determine the Level of Evidence
We determined the level of evidence for each reanalyzed meta-analysis or pooled meta-analysis
to strengthen the associations between statin use and cancer mortality or survival. The criteria to
determine the level of evidence were classified according to the statistical significance by random and
fixed-effects p-value, 95% PI, a small-study effect, a between-study heterogeneity and concordance
between the result of the largest study among each meta-analysis and that of meta-analysis [13,21].
The level of evidence for the association was determined as follows:
2.4.1. Convincing Evidence
There was a strong statistical significance in fixed-effects and random-effects meta-analyses at
p-value < 0.001, 95% PI excluded null, there was no large between-study heterogeneity and no small
study effects. There was a concordance between the result of the largest study and that of meta-analysis
2.4.2. Suggestive Evidence
The significance threshold was crossed for the random summary effects (p < 0.05), but 95% PI
included the null and there was not large between-study heterogeneity and there were no small
study effects.
2.4.3. Weak (Probable) Evidence
The significance threshold was crossed for the random summary effects (p < 0.05), but 95% PI
included the null, there was large between-study heterogeneity or small study effects.
2.4.4. Nonsignificant Associations
The significance threshold was not crossed for the random summary effects (p > 0.05). However,
if the heterogeneity was large, we rechecked the results whether it may be due to differences in the
direction of the effect or it can be due to differences in the size of the association although all studies
may show increased risk. In the latter case, we re-determined the level of evidence again [13,21].
3. Results
3.1. Search Strategy for the Literature and Included Studies for Reanalysis
A total of 335 meta-analyses were retrieved from our PubMed database search. 136 duplicate
articles were initially excluded, and an additional 35 articles were screened by title. Another 102 articles
were excluded after assessing the abstract, and 46 articles were finally excluded after full-text screening
and finally, 16 eligible meta-analyses reporting various kinds of cancer mortality or survival in 11
cancers were finally selected for re-analysis (Figure 1) [22–37]. Overall, all-cause mortality was reported
as outcomes in 11 cancer types, cancer-specific mortality in 8 cancer types, recurrence-free survival in 5
cancer types, progression-free survival in 4 cancer types and disease-free survival in one cancer type
(Tables 1–4).
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Table 1. Summary of each individual meta-analysis on associations of the use of statin and all-cause mortality in various cancers.
Type/Author,
Year
Study
Design
No of
Study
No of Total
Participants
Random
Effects
(Reported)
(ES, 95%CI)
Random
Effects
(Re-Analyzed)
(ES, 95%CI)
Fixed Effects
(Re-Analyzed)
(ES, 95%CI)
Largest
Effect § Egger I
2 (P) † P(Random)
P
(Fixed)
95% PI
(Random)
Small
Study
Effect
Same
Direction Evidence
Bladder cancer
Luo 2015 Obs 1 1117 1.14(0.89–1.44)
1.14
(0.89–1.44)
1.14
(0.89–1.44)
1.14
(0.89–1.44) - - 0.286 0.286 NA - No Non-significant
Breast cancer
Mei 2017 Cohort 7 24,255 0.65(0.43–0.99)
0.65
(0.43–0.98)
0.72
(0.67–0.77)
0.78
(0.72–0.84) 0.541
92.7
(<0.001) 0.042 <0.001 0.15–2.76 No Yes Weak
Liu 2017 Cohort 8 68,373 0.72(0.58–0.89)
0.72
(0.58–0.89)
0.74
(0.69–0.78)
0.46
(0.38–0.55) 0.702
87.4
(<0.001) 0.002 <0.001 0.36–1.44 No Yes Weak
Manthravadi
2016 Cohort 8 40,756
0.66
(0.44–0.99)
0.66
(0.44–0.99)
0.64
(0.57–0.70)
0.39
(0.33–0.46) 0.864
89.0
(<0.001) 0.043 <0.001 0.18–2.40 No Yes Weak
Zhong 2015
(post-diagnostic) Obs 6 51,265
0.75
(0.55–1.02)
0.75
(0.55–1.03)
0.72
(0.64–0.80)
0.47
(0.38–0.59) 0.816
77.8
(<0.001) 0.079 <0.001 0.27–2.09 No No Non-significant
Zhong 2015
(pre-diagnostic) Obs 3 49,116
0.73
(0.62–0.86)
0.73
(0.63–0.86)
0.76
(0.69–0.83)
0.60
(0.45–0.81) 0.501
33.3
(0.269) <0.001 <0.001 0.18–2.95 No Yes Suggestive
Colorectal cancer
Mei 2017 Cohort 9 44,476 0.76(0.68–0.86)
0.76
(0.68–0.86)
0.75
(0.72–0.80)
0.72
(0.67–0.78) 0.793
67.3
(0.002) <0.001 <0.001 0.54–1.07 No Yes Suggestive *
Gray 2016
(post-diagnostic) Obs 11 21,030
0.84
(0.73–0.98)
0.85
(0.73–0.98)
0.84
(0.79–0.90)
0.90
(0.80–1.01) 0.760
69.0
(<0.001) 0.029 <0.001 0.53–1.34 No No Weak
Gray 2016
(pre-diagnostic) Obs 6 44,026
0.85
(0.76–0.96)
0.85
(0.76–0.96)
0.84
(0.80–0.88)
0.85
(0.79–0.92) 0.720
76.0
(<0.001) 0.011 <0.001 0.59–1.24 No Yes Suggestive *
Ling 2015
(post-diagnostic) Cohort 5 10,038
0.93
(0.68–1.27)
0.93
(0.68–1.27)
0.81
(0.73–0.90)
0.75
(0.66–0.84) 0.443
69.4
(0.011) 0.639 <0.001 0.33–2.59 No No Non-significant
Ling 2015
(pre-diagnostic) Cohort 4 12,396
0.73
(0.61–0.88)
0.73
(0.62–0.86)
0.74
(0.66–0.84)
0.81
(0.68–0.96) 0.251
19.9
(0.291) <0.001 <0.001 0.45–1.19 No Yes Suggestive
Cai 2015 (post &
pre-diagnostic) Obs 4 11,786
0.76
(0.61–0.95)
0.79
(0.65–0.95)
0.79
(0.65–0.95)
0.71
(0.54–0.94) 0.587
0.0
(0.447) 0.013 0.013 0.52–1.18 No Yes Suggestive
Cai 2015
(post-diagnostic) Obs 4 15,862
0.76
(0.68–0.85)
0.76
(0.68–0.85)
0.76
(0.68–0.85)
0.75
(0.66–0.84) 0.723
0.0
(0.393) <0.001 <0.001 0.60–0.96 No Yes Convincing
Cai 2015
(pre-diagnostic) Obs 2 10,553
0.70
(0.54–0.91)
0.70
(0.54–0.91)
0.70
(0.54–0.91)
0.71
(0.54–0.94) -
0.0
(0.795) 0.007 0.007 NA - Yes -
Zhong 2015
(post-diagnostic) Obs 6 12,441
0.96
(0.76–1.22)
0.97
(0.75–1.24)
0.86
(0.77–0.95)
0.75
(0.66–0.85) 0.295
65.9
(0.004) 0.792 0.003 0.45–2.09 No No Weak
Zhong 2015
(pre-diagnostic) Obs 3 18,733
0.77
(0.66–0.89)
0.78
(0.69–0.88)
0.79
(0.72–0.87)
0.82
(0.74–0.91) 0.353
31.4
(0.300) <0.001 <0.001 0.27–2.25 No Yes Suggestive
Endocrine-Related Gynecological Cancer
Xie 2017 Obs 9 5449 - 0.70(0.58–0.83)
0.71
(0.63–0.80)
0.66
(0.55–0.80) 0.250
33.3
(0.151) <0.001 <0.001 0.47–1.04 No Yes Suggestive
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Table 1. Cont.
Type/Author, Year StudyDesign
No of
Study
No of Total
Participants
Random
Effects
(Reported)
(ES, 95%CI)
Random
Effects
(Re-Analyzed)
(ES, 95%CI)
Fixed Effects
(Re-Analyzed)
(ES, 95%CI)
Largest
Effect § Egger I
2 (P) † P(Random)
P
(Fixed)
95% PI
(Random)
Small
Study
Effect
Same
Direction Evidence
Endometrial Cancer
Xie 2017 Obs 4 3460 - 0.80(0.62–1.03)
0.84
(0.69–1.01)
0.92
(0.70–1.20) 0.046
0.0
(0.680) 0.083 0.058 0.34–1.89 Yes Yes Non-significant
Zhong 2015
(post-diagnostic) Obs 3 3261
0.89
(0.72–1.09)
0.86
(0.64–1.15)
0.89
(0.72–1.09)
0.92
(0.70–1.20) 0.156
0.0
(0.203) 0.309 0.255 0.05–13.49 No Yes Non-significant
Kidney Cancer
Nayan 2017 Overall 7 11,491 0.74(0.63–0.88)
0.74
(0.63–0.88)
0.78
(0.71–0.87)
0.80
(0.66–0.97) 0.057
51.8
(0.052) 0.001 <0.001 0.47–1.17 Yes Yes Weak
Luo 2015 Obs 3 5881 0.81(0.68–0.96)
0.81
(0.69–0.96)
0.82
(0.72–0.94)
0.84
(0.69–1.00) 0.378
26.0
(0.260) 0.015 0.005 0.19–3.47 No No Suggestive
Lymphoma
Zhong 2015
(post-diagnostic) Obs 3 782
1.15
(0.85–1.55)
1.15
(0.85–1.55)
1.15
(0.85–1.55)
1.23
(0.88–1.71) 0.195
0.0
(0.602) 0.362 0.362 0.16–8.24 No Yes Non-significant
Ovarian Cancer
Li 2018 Obs 7 16,389 0.74(0.63–0.87)
0.74
(0.63–0.87)
0.79
(0.73–0.86)
0.81
(0.72–0.90) 0.061
55.0
(0.038) <0.001 <0.001 0.49–1.11 No Yes Suggestive
Xie 2017 Obs 5 1989 - 0.63(0.54–0.74)
0.63
(0.54–0.74)
0.66
(0.55–0.80) 0.200
0.0
(0.680) <0.001 <0.001 0.48–0.82 No Yes Convincing
Zhong 2015
(post-diagnostic) Obs 2 276
0.39
(0.22–0.71)
0.39
(0.22–0.71)
0.39
(0.22–0.71)
0.24
(0.07–0.87) -
0.0
(0.395) 0.002 0.002 NA - Yes -
Pancreatic Cancer
Jian-Yu 2018 Overall 6 12,057 0.75(0.59–0.90)
0.81
(0.69–0.95)
0.92
(0.87–0.97)
0.94
(0.89–1.01) 0.008
81.1
(<0.001) 0.009 0.001 0.52–1.26 Yes No Weak
Prostate Cancer
Mei 2017 Cohort 10 73,716 0.72(0.63–0.81)
0.72
(0.63–0.81)
0.89
(0.87–0.91)
0.79
(0.76–0.82) 0.044
95.0
(<0.001) <0.001 <0.001 0.46–1.12 Yes Yes Weak
Meng 2016
(post-diagnostic) Obs 7 58,838
0.84
(0.71–0.99)
0.77
(0.68–0.86)
0.80
(0.76–0.83)
0.79
(0.75–0.83) 0.376
72.0
(0.002) <0.001 <0.001 0.54–1.09 No Yes Suggestive *
Meng 2016
(pre-diagnostic) Obs 2 1337
0.56
(0.38–0.85)
0.56
(0.38–0.83)
0.56
(0.38–0.83)
0.57
(0.38–0.85) -
0.0
(0.770) 0.004 0.004 NA - Yes -
Raval 2016 Cohort 6 31,539 0.76(0.63–0.90)
0.76
(0.63–0.91)
0.80
(−0.75–0.86)
0.86
(0.78–0.95) 0.503
71.0
(0.004) 0.004 <0.001 0.44–1.29 No Yes Weak
Luo 2015 Obs 5 22,439 0.82(0.70–0.97)
0.83
(0.70–0.97)
0.85
(0.78–0.93)
0.86
(0.78–0.95) 0.461
46.0
(0.110) 0.022 <0.001 0.52–1.31 No Yes Suggestive
Zhong 2015
(post-diagnostic) Obs 3 18,814
0.59
(0.35–0.99)
0.59
(0.34–1.01)
0.82
(0.75–0.90)
0.86
(0.78–0.95) 0.228
84.1
(0.001) 0.053 <0.001 0.00–406.64 No No Non-significant
Urothelial Tract Cancer
Zhong 2015
(post-diagnostic) Obs 5 9488
0.87
(0.75–1.00)
0.87
(0.75–1.00)
0.87
(0.79–0.95)
0.89
(0.71–1.12) 0.917
52.8
(0.070) 0.049 0.001 0.56–1.34 No No Weak
ES, Effect size; CI, Confidence interval; PI, Prediction interval; Obs, Observational study. § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I2 metric of
inconsistency (95% confidence interval of I2) and P-value of the Cochran Q test for evaluation of heterogeneity. * Convincing or suggestive level of evidence due to the greater number of
studies that decrease risk.
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Table 2. Summary of each individual meta-analysis on associations of the use of statin and cancer-specific mortality in various cancers.
Type/Author, Year StudyDesign
No of
Study
No of Total
Participants
Random Effects
(Reported)
(ES, 95%CI)
Random Effects
(Re-Analyzed)
(ES, 95%CI)
Fixed Effects
(Re-Analyzed)
(ES, 95%CI)
Largest
Effect § Egger I
2 (P) † P(Random)
P
(Fixed)
95% PI
(Random)
Small
Study
Effect
Same
Direction Evidence
Bladder cancer
Luo 2015 Obs 2 2619 1.06(0.87–1.29)
1.06
(0.87–1.29)
1.06
(0.87–1.29)
1.04
(0.84–1.28) -
0.0
(0.590) 0.559 0.559 NA - Yes Non-significant
Breast cancer
Liu 2017 Cohort 8 196,120 0.73(0.59–0.92)
0.73
(0.58–0.92)
0.73
(0.67–0.78)
0.85
(0.74–0.98) 0.997
85.6
(<0.001) 0.007 <0.001 0.34–1.58 No Yes Weak
Manthravadi 2016 Cohort 6 46,970 0.30(0.46–1.06)
0.69
(0.45–1.06)
0.62
(0.54–0.71)
0.35
(0.28–0.45) 0.591
86.0
(<0.001) 0.091 <0.001 0.16–2.92 No No Non-significant
Mansourian 2016 Obs 13 99,610 0.85(0.83–0.87)
0.85
(0.82–0.88)
0.85
(0.83–0.87)
0.83
(0.80–0.86) 0.465
8.6
(0.360) <0.001 <0.001 NA No Yes -
Zhong 2015
(post-diagnostic) Obs 3 49,116
0.60
(0.41–0.88)
0.60
(0.39–0.92)
0.60
(0.52–0.69)
0.47
(0.39–0.57) 0.995
84.1
(<0.001) 0.018 <0.001 0.00–106.05 No Yes Weak
Zhong 2015
(pre-diagnostic) Obs 4 88,235
0.73
(0.61–0.89)
0.77
(0.68–0.87)
0.77
(0.68–0.87)
0.60
(0.35–1.01) 0.002
21.5
(0.428) <0.001 <0.001 0.59–1.01 Yes No Suggestive
Colorectal cancer
Gray 2016
(post-diagnostic) Obs 4 19,152
0.84
(0.68–1.04)
0.84
(0.68–1.04)
0.82
(0.75–0.91)
0.90
(0.77–1.05) 0.887
67.0
(0.030) 0.118 <0.001 0.36–2.00 No Yes Non-significant
Gray 2016
(pre-diagnostic) Obs 6 86,622
0.82
(0.79–0.86)
0.82
(0.79–0.86)
0.82
(0.79–0.86)
0.81
(0.75–0.88) 0.152
0.0
(0.570) <0.001 <0.001 NA No Yes -
Ling 2015
(post-diagnostic) Cohort 3 8667
0.70
(0.60–0.81)
0.70
(0.60–0.82)
0.70
(0.60–0.82)
0.71
(0.61–0.84) 0.219
0.0
(0.535) <0.001 <0.001 0.26–1.87 No Yes Suggestive
Ling 2015
(pre-diagnostic) Cohort 6 74,042
0.80
(0.77–0.84)
0.80
(0.77–0.84)
0.80
(0.77–0.84)
0.79
(0.74–0.85) 0.231
10.8
(0.347) <0.001 <0.001 0.74–0.88 No Yes Convincing
Cai 2015
(pre&post-diagnostic) Obs 6 69,949
0.80
(0.75–0.85)
0.80
(0.75–0.85)
0.80
(0.77–0.85)
0.79
(0.74–0.85) 0.172
19.3
(0.288) <0.001 <0.001 0.71–0.90 No Yes Convincing
Cai 2015
(post-diagnostic) Obs 3 15,023
0.70
(0.60–0.81)
0.70
(0.60–0.82)
0.70
(0.60–0.82)
0.71
(0.61–0.84) 0.219
0.0
(0.535) <0.001 <0.001 0.26–1.87 No Yes Suggestive
Cai 2015
(pre-diagnostic) Obs 5 69,375
0.80
(0.74–0.86)
0.80
(0.74–0.86)
0.81
(0.77–0.85)
0.79
(0.74–0.85) 0.298
28.3
(0.233) <0.001 <0.001 0.67–0.95 No Yes Convincing
Zhong 2015
(post-diagnostic) Obs 4 11,070
0.79
(0.58–1.08)
0.79
(0.58–1.08)
0.77
(0.67–0.88)
0.71
(0.61–0.83) 0.959
60.5
(0.058) 0.141 <0.001 0.24–2.65 No No Weak
Zhong 2015
(pre-diagnostic) Obs 3 25,081
0.82
(0.73–0.91)
0.82
(0.74–0.90)
0.83
(0.78–0.89)
0.77
(0.68–0.88) 0.414
36.2
(0.239) <0.001 <0.001 0.31–2.19 No Yes Suggestive
Endocrine gynecological cancer
Xie 2017 Obs 4 1079 - 0.75(0.55–1.01)
0.72
(0.58–0.90)
0.74
(0.54–1.02) 0.357
35.1
(0.202) 0.057 0.004 0.27–2.09 No Yes Non-significant
Kidney cancer
Nayan 2017 Overall 6 10,337 0.67(0.47–0.94)
0.67
(0.48–0.94)
0.81
(0.71–0.93)
0.85
(0.72–1.01) 0.120
67.0
(0.010) 0.022 0.003 0.25–1.82 No No Weak
Luo 2015 Obs 2 3273 0.71(0.35–1.50)
0.72
(0.35–1.51)
0.84
(0.64–1.11)
1.02
(0.74–1.39) –
82.0
(0.020) 0.389 0.222 NA - Yes Non-significant
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Table 2. Cont.
Type/Author, Year StudyDesign
No of
Study
No of Total
Participants
Random Effects
(Reported)
(ES, 95%CI)
Random Effects
(Re-Analyzed)
(ES, 95%CI)
Fixed Effects
(Re-Analyzed)
(ES, 95%CI)
Largest
Effect § Egger I
2 (P) † P(Random)
P
(Fixed)
95% PI
(Random)
Small
Study
Effect
Same
Direction Evidence
Ovarian cancer
Li 2018 Obs 3 27,690 0.87(0.80–0.95)
0.87
(0.80–0.95)
0.87
(0.80–0.95)
0.93
(0.81–1.08) 0.577
0.0
(0.411) 0.002 0.002 0.50–1.54 No No Weak
Prostate cancer
Meng 2016
(post-diagnostic) Obs 4 57,058
0.64
(0.52–0.79)
0.64
(0.52–0.79)
0.73
(0.69–0.77)
0.74
(0.70–0.79) 0.254
82.0
(<0.001) <0.001 <0.001 0.27–1.55 No Yes Suggestive *
Meng 2016
(pre-diagnostic) Obs 6 35,684
0.53
(0.29–0.98)
0.54
(0.37–0.78)
0.78
(0.72–0.84)
0.81
(0.75–0.88) 0.019
77.0
(<0.001) 0.001 <0.001 0.18–1.64 Yes Yes Weak
Raval 2016 Cohort 5 21,306 0.76(0.64–0.89)
0.76
(0.64–0.89)
0.76
(0.69–0.84)
0.76
(0.66–0.88) 0.593
30.0
(0.150) 0.001 <0.001 0.49–1.17 No Yes Suggestive
Luo 2015 Obs 7 28,897 0.70(0.59–0.83)
0.70
(0.60–0.83)
0.74
(0.68–0.82)
0.76
(0.66–0.88) 0.011
43.0
(0.100) <0.001 <0.001 0.48–1.04 Yes Yes Suggestive
Zhong 2015
(post-diagnostic) Obs 3 19,322
0.77
(0.70–0.85)
0.77
(0.70–0.85)
0.77
(0.70–0.85)
0.76
(0.66–0.88) 0.973
0.0
(0.970) <0.001 <0.001 0.38–1.54 No Yes Suggestive
Zhong 2015
(pre-diagnostic) Obs 3 5460
0.44
(0.20–0.93)
0.44
(0.21–0.92)
0.72
(0.62–0.82)
0.78
(0.67–0.90) 0.148
86.3
(0.001) 0.029 <0.001
Not
estimable No Yes Suggestive *
Urothelial tract cancer
Zhong 2015
(post-diagnostic) Obs 4 6880
0.86
(0.65–1.16)
0.87
(0.66–1.14)
0.87
(0.76–1.01)
0.86
(0.72–1.03) 0.901
61.8
(0.073) 0.307 0.070 0.30–2.53 No Yes Non-significant
ES, Effect size; CI, Confidence interval; PI, Prediction interval; Obs, Observational study. § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I2 metric of
inconsistency (95% confidence interval of I2) and P-value of the Cochran Q test for evaluation of heterogeneity. * Convincing or suggestive level of evidence due to the greater number of
studies that decrease risk.
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Table 3. Summary of each individual meta-analysis on associations of the use of statin and recurrence-free survival, progression-free survival and disease-free survival
in various cancers.
Type/Author, Year StudyDesign
No of
Study
No of Total
Participants
Random Effects
(Reported)
(ES, 95%CI)
Random Effects
(Re-Analyzed)
(ES, 95%CI)
Fixed Effects
(Re-Analyzed)
(ES, 95%CI)
Largest
Effect § Egger I
2 (P) † P(Random)
P
(Fixed)
95% PI
(Random)
Small
Study
Effect
Same
Direction Evidence
Recurrence-free survival
Bladder cancer
Luo 2015 Obs 3 3571 1.05(0.94–1.18)
1.06
(0.94–1.19)
1.06
(0.94–1.19)
1.04
(0.96–1.24) 0.844
0.0
(0.950) 0.375 0.375 0.47–2.36 No Yes Non-significant
Breast cancer
Manthravadi 2016 Cohort 10 32,373 0.64(0.53–0.79)
0.64
(0.52–0.79)
0.69
(0.60–0.79)
0.80
(0.64–1.00) 0.093
44.0
(0.070) <0.001 <0.001 0.38–1.09 Yes Yes Suggestive
Colorectal cancer
Cai 2015 Obs 2 1233 0.98(0.36–2.70)
0.98
(0.36–2.70)
1.12
(0.58–2.15)
1.28
(0.64–2.54) –
26.1
(0.345) 0.975 0.730 NA - Yes Non-significant
Kidney cancer
Nayan 2017 Overall 4 2197 0.97(0.89–1.06)
0.97
(0.89–1.06)
1.00
(0.99–1.01)
1.09
(0.65–1.81) 0.364
55.2
(0.082) 0.524 0.899 0.70–1.36 No Yes Non-significant
Luo 2015 Obs 3 5080 0.91(0.54–1.55)
0.91
(0.54–1.55)
1.00
(0.81–1.23)
1.22
(0.95–1.57) 0.783
72.0
(0.030) 0.736 0.991 0.47–2.36 No Yes Non-significant
Prostate cancer
Park 2013 Cohort 13 21,185 0.90(0.74–1.08)
0.90
(0.74–1.08)
0.92
(0.84–1.00)
0.99
(0.83–1.18) 0.649
69.6
(<0.001) 0.252 0.057 0.48–1.67 No Yes Non-significant
Progression-free survival
Bladder cancer
Luo 2015 Obs 2 2069 0.87(0.65–1.15)
0.87
(0.65–1.15)
0.87
(0.65–1.15)
0.77
(0.52–1.13) 0.461
0.0
(0.370) 0.320 0.320 NA No Yes Non-significant
Endocrine gynecological cancer
Xie 2017 Obs 3 421 - 0.69(0.46–1.02)
0.68
(0.49–0.93)
0.65
(0.39–1.07) 0.439
33.6
(0.222) 0.066 0.018 0.02–27.87 No Yes Non-significant
Kidney cancer
Nayan 2017 Overall 2 4965 0.92(0.51–1.65)
0.92
(0.51–1.65)
1.00
(0.82–1.23)
0.67
(0.47–0.96) –
86.2
(0.007) 0.772 0.996 NA - No Non-significant
Prostate cancer
Luo 2015 Obs 5 6032 0.84(0.62–1.14)
0.84
(0.62–1.14)
0.87
(0.71–1.05)
1.10
(0.78–1.56) 0.607
52
(0.080) 0.260 0.148 0.34–2.10 No Yes Non-significant
Disease-free survival
Colorectal cancer
Cai 2015 Obs 2 1233 1.13(0.78–1.62)
1.13
(0.78–1.62)
1.13
(0.78–1.62)
1.07
(0.68–1.67) -
0.0
(0.691) 0.514 0.514 NA - Yes Non-significant
ES, Effect size; CI, Confidence interval; PI, Prediction interval; Obs, Observational study; § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I2 metric of
inconsistency (95% confidence interval of I2) and P-value of the Cochran Q test for evaluation of heterogeneity.
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Table 4. Summary of the meta-analysis results by pooling all the datasets on associations of statin and the mortality or survival.
Cancer Type No ofStudies
No of Total
Participants
Random
Effects
(RR, 95%CI)
P
(Random)
Fixed Effects
(RR, 95%CI)
P
(Fixed)
Largest Effect §
(RR, 95%CI) D/N/I Egger I
2 (P) † 95% PI(Random)
95% PI
(Fixed)
Concordant
Direction Evidence
All-cause mortality
Bladder cancer 1 1117 1.14 (0.89–1.44) 0.286 1.14 (0.89–1.44) 0.286 1.14 (0.89–1.44) 0/1/0 - - NA NA No Non-significant
Breast cancer 20 160,806 0.65 (0.55–0.77) <0.001 0.66 (0.62–0.70) <0.001 0.54 (0.44–0.67) 12/0/8 0.787 85.2 (<0.001) 0.33–1.29 0.34–1.28 Yes Suggestive *
Colorectal cancer 24 85,231 0.81 (0.75–0.88) <0.001 0.82 (0.80–0.86) <0.001 0.82 (0.74–0.90) 15/8/1 0.444 68.1 (<0.001) 0.60–1.10 0.61–1.11 Yes Suggestive *
Endocrine-related
gynecological cancer 9 5449 0.70 (0.58–0.83) <0.001 0.71 (0.63–0.80) <0.001 0.66 (0.55–0.80) 4/5/0 0.250 33.3 (0.151) 0.47–1.04 0.49–1.03 Yes Suggestive
Endometrial cancer 4 3460 0.80 (0.62–1.03) 0.083 0.84 (0.69–1.01) 0.058 0.92 (0.70–1.20) 1/3/0 0.046 36.1 (0.196) 0.34–1.89 0.38–1.82 Yes Non-significant
Kidney cancer 7 11,491 0.74 (0.63–0.88) 0.001 0.78 (0.71–0.87) <0.001 0.80 (0.66–0.98) 4/3/0 0.057 51.8 (0.053) 0.47–1.17 0.51–1.20 Yes Weak
Lymphoma 3 782 1.15 (0.85–1.55) 0.362 1.15 (0.85–1.55) 0.362 1.23 (0.88–1.71) 0/3/0 0.195 0.0 (0.602) 0.16–8.24 0.16–8.24 Yes Non-significant
Ovarian cancer 7 16,307 0.74 (0.63–0.87) <0.001 0.79 (0.73–0.86) <0.001 0.81 (0.72–0.90) 4/3/0 0.067 0.0 (0.411) 0.49–1.12 0.55–1.15 Yes Suggestive
Pancreatic cancer 6 12,057 0.81 (0.69–0.95) 0.009 0.92 (0.87–0.97) 0.001 0.94 (0.89–1.01) 3/3/0 0.008 81.1 (<0.001) 0.52–1.26 0.62–1.36 No Weak
Prostate cancer 21 95,128 0.73 (0.67–0.81) <0.001 0.89 (0.88–0.91) <0.001 0.79 (0.75–0.83) 15/6/0 0.002 89.9 (<0.001) 0.50–1.08 0.61–1.30 No Weak
Urothelial tract cancer 5 9488 0.87 (0.75–1.00) 0.049 0.87 (0.79–0.95) 0.001 0.89 (0.71–1.12) 2/3/0 0.917 52.8 (0.070) 0.56–1.34 0.58–1.29 No Weak
Cancer-specific mortality
Bladder cancer 2 2619 1.06 (0.87–1.29) 0.559 1.06 (0.87–1.29) 0.559 1.04 (0.84–1.28) 0/2/0 - 0.0 (0.590) NA NA Yes Non-significant
Breast cancer 28 424,694 0.71 (0.65–0.78) <0.001 0.82 (0.80–0.84) <0.001 0.83 (0.80–0.86) 12/16/0 0.044 84.0 (<0.001) 0.50–1.02 0.58–1.16 Yes Weak
Colorectal cancer 13 118,996 0.81 (0.78–0.85) <0.001 0.82 (0.79–0.85) <0.001 0.77 (0.69–0.87) 8/5/0 0.282 26.2 (0.180) 0.72–0.92 0.74–0.90 Yes Convincing
Endocrine-related
gynecological cancer 4 1079 0.75 (0.55–1.01) 0.057 0.72 (0.58–0.90) 0.004 0.74 (0.54–1.02) 1/3/0 0.357 35.1 (0.202) 0.27–2.09 0.29–1.82 Yes Non-significant
Kidney cancer 6 10,337 0.67 (0.48–0.94) 0.022 0.81 (0.71–0.93) 0.003 0.85 (0.72–1.01) 3/3/0 0.120 66.6 (0.011) 0.25–1.82 0.33–1.98 No Weak
Ovarian cancer 3 27,690 0.87 (0.80–0.95) 0.002 0.87 (0.80–0.95) 0.002 0.93 (0.81–1.08) 1/2/0 0.577 0.0 (0.411) 0.50–1.54 0.50–1.54 No Weak
Prostate cancer 15 101,378 0.66 (0.58–0.74) <0.001 0.74 (0.71–0.78) <0.001 0.74 (0.70–0.79) 11/4/0 0.010 68.3 (<0.001) 0.47–0.93 0.54–1.02 Yes Weak
Urothelial tract cancer 4 6880 0.87 (0.66–1.14) 0.307 0.87 (0.76–1.01) 0.070 0.86 (0.72–1.03) 1/3/0 0.901 61.8 (0.073) 0.30–2.53 0.34–2.22 Yes Non-significant
Recurrence-free survival
Bladder cancer 3 3571 1.06 (0.94–1.19) 0.375 1.06 (0.94–1.19) 0.375 1.04 (0.96–1.24) 0/3/0 0.844 0.0 (0.950) 0.47–2.36 0.47–2.36 Yes Non-significant
Breast cancer 10 32,373 0.64 (0.52–0.79) <0.001 0.69 (0.60–0.79) <0.001 0.80 (0.64–1.00) 6/4/0 0.093 44.0 (0.070) 0.38–1.09 0.42–1.14 Yes Weak
Colorectal cancer 2 1233 0.98 (0.36–2.70) 0.975 1.12 (0.58–2.15) 0.730 1.28 (0.64–2.54) 0/2/0 - 26.1 (0.345) NA NA Yes Non-significant
Kidney cancer 4 2197 0.97 (0.89–1.06) 0.524 1.00 (0.99–1.01) 0.899 1.09 (0.65–1.81) 1/3/0 0.364 56.8 (0.074) 0.70–1.36 0.36–1.31 Yes Non-significant
Prostate cancer 13 21,185 0.90 (0.74–1.08) 0.252 0.92 (0.84–1.00) 0.057 0.99 (0.83–1.18) 5/7/1 0.649 69.6 (<0.001) 0.48–1.67 0.50–1.66 Yes Non-significant
Progression-free survival
Bladder cancer 2 2069 0.87 (0.65–1.15) 0.320 0.87 (0.65–1.15) 0.320 0.77 (0.52–1.13) 0/2/0 0.461 0.0 (0.370) NA NA Yes Non-significant
Endocrine-related
gynecological cancer 3 421 0.69 (0.46–1.02) 0.066 0.68 (0.49–0.93) 0.018 0.65 (0.39–1.07) 1/2/0 0.439 33.6 (0.222) 0.02–27.87 0.02–19.47 Yes Non-significant
Kidney cancer 2 4965 0.92 (0.51–1.65) 0.772 1.00 (0.82–1.23) 0.996 0.67 (0.47–0.96) 1/1/0 - 86.2 (0.007) NA NA No Non-significant
Prostate cancer 5 6032 0.84 (0.62–1.14) 0.260 0.87 (0.71–1.05) 0.148 1.10 (0.78–1.56) 2/3/0 0.607 52 (0.080) 0.34–2.10 0.38–2.00 Yes Non-significant
Disease-free survival
Colorectal cancer 2 1,233 1.13 (0.78–1.62) 0.514 1.13 (0.78–1.62) 0.514 1.07 (0.68–1.67) 0/2/0 - 0.0 (0.691) NA NA Yes Non-significant
D/N/I, Decreasing risk/No difference/Increasing risk; RR, Risk ratio; CI, Confidence interval; PI, Prediction. § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis.
† I2 metric of inconsistency (95% confidence interval of I2) and P-value of the Cochran Q test for evaluation of heterogeneity. * Suggestive or convincing level of evidence due to the greater
number of studies that decrease risk in which a high heterogeneity is due to differences in the effect size of the association.
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3.2. The Effect of Statin on All-Cause Mortality in 11 Cancers
The results of each meta-analysis on the effect of statin on all-cause mortality in various cancer
types are summarized in Table 1 and the results of meta-analyses in which all the individual datasets
are pooled are summarized in Table 4.
There were no associations between statin use and all-cause mortality in three cancer types
(bladder, endometrial and urothelial tract cancer). In breast cancer, three meta-analyses which included
any statin use (all weak evidence due to high heterogeneity) and one with pre-diagnostic statin use
(suggestive evidence) showed the beneficial effect of statin on all-cause mortality, while there was no
significant association between post-diagnostic statin use and all-cause mortality in one meta-analysis.
When the individual datasets were all pooled (n = 20), the evidence for the effect of statin use in
preventing all-cause mortality in breast cancer was suggestive despite a high heterogeneity because it
was due to differences in the effect size of the association.
In colorectal cancer, nine of the 10 meta-analyses showed the beneficial effect of statin on all-cause
mortality, while only one older meta-analysis showed no significant association between post-diagnostic
statin use and all-cause mortality. When the individual datasets were all pooled (n = 24), the evidence
for the effect of statin use in preventing all-cause mortality in colorectal cancer was suggestive despite
a high heterogeneity, because it was due to differences in the effect size of the association.
In endocrine-related gynecological cancer, there was only one meta-analysis (n = 9) which showed
a beneficial effect of statin on all-cause mortality with suggestive evidence.
In kidney cancer, there were two meta-analyses that showed a beneficial effect of statin on all-cause
mortality with one suggestive and the other weak evidence. When the individual datasets were all
pooled (n = 7), the evidence for the effect of statin use in preventing all-cause mortality in kidney
cancer was weak due to small study effects and high heterogeneity.
In ovarian cancer, there were three meta-analyses that showed a beneficial effect of statin on
all-cause mortality with one convincing, the other suggestive and another not estimable. When the
individual datasets were all pooled (n = 7), the evidence for the effect of statin use in preventing
all-cause mortality in ovarian cancer was suggestive.
In pancreatic cancer, there was only one meta-analysis (n = 6) which showed a beneficial effect of
statin on all-cause mortality with weak evidence due to small study effects and high heterogeneity.
In prostate cancer, five of the six meta-analyses showed the beneficial effect of statin on all-cause
mortality (two suggestive, two weak and one not estimable), while only one older meta-analysis
showed no significant association between post-diagnostic statin use and all-cause mortality. When
the individual datasets were all pooled (n = 21), the evidence for the effect of statin use in preventing
all-cause mortality in prostate cancer was weak due to small study effects and high heterogeneity.
In urothelial tract cancer, there was only one meta-analysis (n = 5) which showed a beneficial
effect of statin on all-cause mortality with weak evidence due to high heterogeneity.
3.3. The Effect of Statin on Cancer-Specific Mortality in 8 Cancers
The results of each meta-analysis on the effect of statin on cancer-specific mortality in various
cancer types are summarized in Table 2 and the results of meta-analyses in which all the individual
datasets are pooled are summarized in Table 4.
There was only one meta-analysis for each in three cancer types (bladder, endocrine-related
gynecological cancer, and urothelial tract cancer) and no associations were found between statin use
and cancer-specific mortality in each cancer type.
In breast cancer, four of the five meta-analyses showed the beneficial effect of statin on cancer-specific
mortality (one suggestive, two weak and one not estimable, but at least suggestive), while only one
meta-analysis showed no significant association. When the individual datasets were all pooled (n = 28),
the evidence for the effect of statin use in preventing cancer-specific mortality in breast cancer was weak
due to small study effects and high heterogeneity.
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In colorectal cancer, eight of the nine meta-analyses showed the beneficial effect of statin on
cancer-specific mortality, while only one older meta-analysis showed no significant association between
post-diagnostic statin use and cancer-specific mortality. When the individual datasets were all pooled
(n = 13), the evidence for the effect of statin use in preventing cancer-specific mortality in colorectal
cancer was convincing.
In kidney cancer, there were two meta-analyses that showed a beneficial effect of statin on
cancer-specific mortality with one weak and the other not significant in older meta-analysis. When
the individual datasets were all pooled (n = 6), the evidence for the effect of statin use in preventing
cancer-specific mortality in kidney cancer was weak due to high heterogeneity.
In ovarian cancer, there was only one meta-analysis (n = 3) which showed a beneficial effect of
statin on cancer-specific mortality with weak evidence due to the presence of small study effect.
In prostate cancer, all six of the meta-analyses showed the beneficial effect of statin on cancer-specific
mortality (five suggestive and one weak). When the individual datasets were all pooled (n = 15), the
evidence for the effect of statin use in preventing cancer-specific mortality in prostate cancer was weak
due to small study effects and high heterogeneity.
3.4. The Effect of Statin on Recurrence-Free Survival, Progression-Free Survival, and Disease-Free Survival
The results of each meta-analysis on the effect of statin on recurrence-free survival, progression-free
survival or disease-free survival in various cancer types are summarized in Table 3 and the pooled
results of meta-analyses in recurrence-free survival for kidney cancer are summarized in Table 4.
Recurrence-free survival was measured as outcome for the preventive effect of statin in five cancers
(bladder, breast, colorectal, kidney and prostate cancer) and no associations were found between statin
use and recurrence-free survival in each cancer type in four cancers (bladder, colorectal, kidney and
prostate cancer) and there was only one meta-analysis (n = 10) which showed a beneficial effect of
statin on recurrence-free survival in breast cancer with a suggestive evidence.
Progression-free survival was measured as an outcome for the preventive effect of statin in
four cancers (bladder, endocrine-related gynecological cancer, kidney, and prostate cancer) and no
associations were found in these cancers.
Disease-free survival was measured as an outcome for the preventive effect of statin in one cancer
(colorectal cancer) and no association was found.
4. Discussion
The purpose of this umbrella review of previous meta-analysis and re-analysis of meta-analyses,
including all the individual studies was to highlight the potential effects of statin use on cancer mortality
or survival. Our team recently examined the association between statin use and cancer incidence,
and we found out that there were substantial weak or not significant associations [13]. We further
analyzed the data from 16 meta-analyses to evaluate the use of statins and cancer mortality or survival.
With only using random-effects p-value and effect size with 95% confidence interval (CI) [38], which
is a conventional interpretation of current meta-analysis, 14 of 29 associations of cancer mortality or
survival showed a statistically significant preventive effect of statin on these outcomes. Among these
outcomes, the use of statin significantly decreased the cancer-specific mortality of colorectal cancer
supported with a convincing level of evidence. These studies of colorectal cancer on cancer-specific
mortality were performed with four meta-analyses with 13 individual studies including a total of
118,996 patients. The main findings with the determined level of evidence were summarized in Table 5.
This outcome can be fortified with the preclinical studies of the anticancer effects of adjuvant
statin on colorectal cancer [39]. Several mechanisms responsible for anticancer effect on colorectal
cancer were inducing apoptosis by down-regulating of anti-apoptotic proteins [40], inhibition of
cellular proliferation [41], or inhibition of angiogenesis [42]. Recent studies present that statin inhibits
the formation of mevalonate from HMG-CoA, it subsequently inhibits the Ras/Rho prenylation and
downstream reactions, expected to overcome the resistance of anti-epidermal growth factor receptor
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(EGFR) therapy in patients with K-RAS mutation [43]. These beneficial effects of statin on cancer,
especially on colorectal cancer, may largely overlapping and can be applied both in the field of cancer
prevention and adjuvant cancer therapy.
Table 5. Evidence of association between statin use and mortality or survival outcomes.
Evidence
Category All-Cause Mortality *
Cancer-Specific
Mortality
Recurrence Free
Survival
Progression-Free
Survival
Disease-Free
Survival
Convincing - Colorectal cancer(0.82; 0.79–0.85) - - -
Suggestive
Breast cancer
(0.65; 0.55–0.77)
Colorectal cancer
(0.82; 0.75–0.88)
Endocrine-related
gynecological cancer
(0.71; 0.58–0.83)
Ovarian cancer
(0.74; 0.63–0.87)
- - - -
Weak
Kidney cancer
(0.73; 0.71–0.87)
Pancreatic cancer
(0.81; 0.69–0.95)
Prostate cancer
(0.89; 0.88–0.91)
Urothelial tract cancer
(0.87; 0.75–1.00)
Breast cancer
(0.71; 0.65–0.78)
Kidney cancer
(0.67; 0.48–0.94)
Ovarian cancer
(0.87; 0.80–0.95)
Prostate cancer
(0.66; 0.58–0.74)
Breast cancer
(0.64; 0.52–0.79) - -
Non-significant
Bladder cancer
Endometrial cancer
Lymphoma
Bladder cancer
Endocrine-related
gynecological cancer
Urothelial tract cancer
Bladder cancer
Colorectal cancer
Kidney cancer
Prostate cancer
Bladder cancer
Endocrine-related
gynecological cancer
Kidney cancer
Prostate cancer
Colorectal
cancer
* Results with statistically significant association (convincing, suggestive and weak) were presented with its random
summary effects and 95% confidence interval.
However, besides the case of colorectal cancer, statin’s effect on other types of cancer mortality
was supported by a weak or non-significant level of evidence. This can be addressed with possible
explanations. First, there was a relatively limited number of studies. Colorectal and breast cancer
show a high rate of incidence and mortality worldwide, which leads to a large number of RCTs and
observational studies [44]. However, underpowered-studies supported by the small number of studies
have limitations to be validated [45]. Due to this reason, further updated meta-analyses should include
a large number of individual studies. Also, some cancers innately have poor prognosis or can be
detected in a more progressed stage. Cancers such as bladder or pancreatic cancer have a relatively
low survival rate in the general population, which may attenuate the effect of statin’s benefit.
Among pooled meta-analyses of all-cause mortality of patients with 11 types of cancer, eight of
them showed a negative association and four of them had a suggestive level of evidence (Table 4).
Above all, statin showed a significantly conspicuous effect on all-cause mortality of breast and colorectal
cancer patients, supported by a sufficient number of meta-analyses with suggestive or convincing
level. Besides, in case of breast cancer, the disease-specific mortality (in this case, breast cancer-specific
mortality) showed a negative association with the use of statin, supported by the lower magnitude of
effect size and weaker level of evidence. All-cause mortality is a widely adopted result variable of
many trials and observational studies because it can present any unexpected lethal outcomes of trials,
such as non-cardiovascular outcomes in patients with hyperlipidemia [46]. However, this should be
carefully interpreted since most of the statin users have risk factors of cardiovascular diseases or higher
rate of cardiovascular death, use of statin can act as confounding factors of the outcome measures.
Most of the results observed the survival rate of cancer (recurrence-free survival, progression-free
survival, and disease-free survival) were shown to have non-significant results, except for the results
of breast cancer recurrence-free survival. Since studies of these kinds of outcome measures have
not widely performed, the sample sizes of individual meta-analyses are limited, which may lead
to false-positive estimates. In case of breast cancer recurrence-free survival, it only includes one
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meta-analysis [25], but with an adequate number of individual studies and sample sizes. To robust the
statistical significance, further study should be conducted.
Meta-analysis is an important research design for appraising evidence and guiding medical
practice and health policy by combining data from many studies and umbrella review (reviews
of previously published systematic reviews or meta-analyses) emerged as an important method of
evidence synthesis because it can provide a wider picture compared with a meta-analysis which is
limited to one treatment comparison or even one outcome [47]. Recently, however, mass production
of flawed meta-analysis also has been a problem in the medical field [48]. Meta-analysis has its own
several limitations such as heterogeneity or publication bias. Also, overlapping meta-analyses on
the same topic have been an important issue [49,50], because they often show conflicting results
among them and our umbrella review also showed that there were many overlapped meta-analyses
with discordant results. The most updated meta-analysis should include all the previous individual
studies, but some previous studies are frequently missing in the last meta-analysis despite extensive
search strategy due to not reviewing the previous meta-analysis on the same topic, which can lead to
misleading results. There are several ways to overcome this problem, and therefore, we performed
re-analysis by pooling all the individual studies datasets in addition to analysis of each meta-analysis.
Due to these several problems, the results of meta-analysis should be interpreted with caution and
recent umbrella reviews suggest the use of several criteria for determining level of evidence such as the
degree of p-value, the statistical significance in both random and fixed effect models, between-study
heterogeneity, small study effect, and 95% PI, which is more strict than the p-value alone [20,21,51].
The strength of evidence reinforces the results from the meta-analyses and assists to choose the best
evidence for the decision.
Our study has several limitations: (1) we only included the re-analyzable meta-analyses for
re-analysis, (2) potential confounding factors differed across the individual studies (3) individual
observational studies themselves can have biases, (4) each meta-analysis might include erroneous
individual studies, (5) some statistics such as 95% PI and Egger’s tests cannot be done if there were
small number of individual studies, (6) the criteria we used may not be definitive criteria for assessing
the strength of evidence, (7) the dose-effect of statin was beyond the scope of our analysis, (8) and
the subgroup analyses of the effects such as adjuvant therapy or underlying patients’ conditions were
also beyond our scope and were not performed due to lack of studies for the analysis. Future studies
should be performed considering limitations of individual meta-analyses and potential biases, and
also should consider the dose-dependent effect of statin.
5. Conclusions
Our umbrella review extensively re-analyzed the meta-analyses on the associations between
statin use and cancer mortality or survival. 14 of 29 studies on statin-cancer mortality were significant.
Especially, the use of statin was significantly associated with a reduction of cancer-specific mortality
of colorectal cancer supported by a convincing level of evidence, which can be interpreted that it
has a noteworthy association. Although there have been extensive epidemiologic or meta-analysis
studies on the associations of statin use with cancer mortality or survival and report many strong
claims of significance for the associations, only a minor portion of these associations have convincing
or suggestive associations without biases. Our findings would give a clue to clinicians and researchers
and help understand the true associations.
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